The worlds first somatic clonal disease model monkeys were born in China

category:Internet click:422
 The worlds first somatic clonal disease model monkeys were born in China


10 years of tackling key problems + 1 billion dollars of investment is almost the standard allocation of new drugs. However, even if the investment is so huge, the probability of failure is still over 90%. The scientific community believes that the fundamental reason is the lack of experimental disease model monkeys with identical genetic background.

Five somatic cell cloned monkeys with biological rhythm disorders (taken on November 27, 2018). Xinhua News Agency (provided by Institute of Neuroscience, Chinese Academy of Sciences)

Rhesus monkeys are commonly used as laboratory animals in the world. In 2017, the successful cloning of Zhongzhong and Huahua solved the problem of keeping the genetic background of wild rhesus monkeys consistent, but failed to solve the problem of constructing disease model monkeys. This time, on the premise of strictly abiding by scientific ethics, Zhang Hongjun, Sun Qiang and Liu Zheng of the Institute of Neuroscience of the Chinese Academy of Sciences obtained five diseased monkeys with different severity of clock disorder by knocking out the key genes for the first time. Then, they selected a rhesus monkey with the most obvious disorder characteristics as the prototype of cloning and collected the details of its somatic cells. Five cloned disease monkeys were finally obtained from the nucleus. At present, the oldest is over half a year old and the youngest is over three months old. So far, the construction of disease model monkeys has been overcome.

Industry experts believe that the nuclei of Zhongzhong and Huahua come from female fetal monkeys, while the nuclei of the five cloned monkeys come from male young diseased monkeys, which require higher operation requirements and are more difficult to achieve. This indicates that Chinas somatic cell cloning technology is maturing.

On January 22, the fathers of five somatic cell cloned monkeys with biological rhythm disorders were photographed in the monkey room of the non-human primate research platform of the Institute of Neuroscience of the Chinese Academy of Sciences. Jin Liwang, a reporter from Xinhua News Agency, currently uses a large number of laboratory animals for drug safety and metabolic testing every year in drug research and development worldwide, and also recruits a large number of clinical trial population for drug efficacy evaluation. With the development of mass cloning technology for disease model monkeys, the number of laboratory animals in the world is expected to decrease dramatically in the future, and the proportion of ineffective drugs used by clinical trial population will also be greatly reduced. Academician Pu Muming, director of Institute of Neuroscience, Chinese Academy of Sciences, said that next step, the team will continue to optimize gene modification + somatic cell cloning technology, develop cloned monkey models with various brain diseases, use them in basic research to draw whole brain nerve connection map, use them in transformation applications to develop more effective therapeutic methods for brain diseases, and further improve the efficiency of drug research and development. u3002 Source: Xinhua responsible editor: Wang Fengzhi_NT2541

On January 22, the fathers of five somatic cell cloned monkeys with biological rhythm disorders were photographed in the monkey room of the non-human primate research platform of the Institute of Neuroscience of the Chinese Academy of Sciences. Xinhua News Agency reporter Jin Liwang

At present, a large number of laboratory animals are used for drug safety and metabolic testing in global drug research and development every year, and a large number of clinical trial population will be recruited for drug efficacy evaluation. With the development of mass cloning technology for disease model monkeys, the number of laboratory animals in the world is expected to decrease dramatically in the future, and the proportion of ineffective drugs used by clinical trial population will also be greatly reduced.

Academician Pu Muming, director of Institute of Neuroscience, Chinese Academy of Sciences, said that next step, the team will continue to optimize gene modification + somatic cell cloning technology, develop cloned monkey models with various brain diseases, use them in basic research to draw whole brain nerve connection map, use them in transformation applications to develop more effective therapeutic methods for brain diseases, and further improve the efficiency of drug research and development. u3002